ArticleExperimental physiology2009
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.
Article in Experimental physiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Renin-angiotensin system gene expression and neurodegenerative diseases.Journal of the renin-angiotensin-aldosterone system : JRAAS · 2016Pooled it
- Hi1a Improves Sensorimotor Deficit following Endothelin-1-Induced Stroke in Rats but Does Not Improve Functional Outcomes following Filament-Induced Stroke in Mice.ACS pharmacology & translational science · 2024Article
- Inhibition of insulin-regulated aminopeptidase confers neuroprotection in a conscious model of ischemic stroke.Scientific reports · 2023Article
- Sigma-1 Receptor Activation Improves Oligodendrogenesis and Promotes White-Matter Integrity after Stroke in Mice with Diabetic Mellitus.Molecules (Basel, Switzerland) · 2023Article
- Review
- The counter regulatory axis of the renin angiotensin system in the brain and ischaemic stroke: Insight from preclinical stroke studies and therapeutic potential.Cellular signalling · 2020Review
- The Role of Sartans in the Treatment of Stroke and Subarachnoid Hemorrhage: A Narrative Review of Preclinical and Clinical Studies.Brain sciences · 2020Review
- Assessing the effects of Ang-(1-7) therapy following transient middle cerebral artery occlusion.Scientific reports · 2019Article
- Impact of Early High-protein Diet on Neurofunctional Recovery in Rats with Ischemic Stroke.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Post-stroke angiotensin II type 2 receptor activation provides long-term neuroprotection in aged rats.PloS one · 2017Article
- Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension.PloS one · 2017Article
- Therapeutic potential of the renin angiotensin system in ischaemic stroke.Experimental & translational stroke medicine · 2016Review
- Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke.Current hypertension reports · 2015Review
- The protective arms of the renin-angiontensin system in stroke.Current hypertension reports · 2014Review
- Bradykinin antagonist counteracts the acute effect of both angiotensin-converting enzyme inhibition and of angiotensin receptor blockade on the lower limit of autoregulation of cerebral blood flow.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2014Article
- Promising neuroprotective effects of the angiotensin-(1-7)-angiotensin-converting enzyme 2-Mas axis in stroke.Experimental physiology · 2014Article
- Centrally administered angiotensin-(1-7) increases the survival of stroke-prone spontaneously hypertensive rats.Experimental physiology · 2014Article
- Cerebroprotective action of angiotensin peptides in stroke.Clinical science (London, England : 1979) · 2014Review
- Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke.Neuropharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Endogenous levels of angiotensin II (Ang II) are increased in the cortex and hypothalamus following stroke, and Ang II type 1 receptor blockers (ARBs) have been shown to attenuate the deleterious effects in animal stroke models using middle cerebral artery (MCA) intraluminal occlusion procedures. However, the endothelin-1 (ET-1)-induced middle cerebral artery occlusion (MCAO) model of cerebral ischaemia is thought to more closely mimic the temporal events of an embolic stroke. This method provides rapid occlusion of the MCA and a gradual reperfusion that lasts for 16-22 h. The aim of the present study was to evaluate whether systemic administration of an ARB prior to ET-1-induced MCAO would provide cerebroprotection during this model of ischaemic stroke. Injection of 3 microl of 80 microM ET-1 adjacent to the MCA resulted in complete occlusion of the vessel that resolved over a period of 30-40 min. Following ET-1-inducedMCAO, rats had significant neurological impairment, as well as an infarct that consisted of 30% of the ipsilateral grey matter. Systemic pretreatment with 0.2 mg kg(-1) day(-1) candesartan for 7 days attenuated both the infarct size and the neurological deficits caused by ET-1-induced MCAO without altering blood pressure. This study confirms the cerebroprotective properties of ARBs during ischaemic stroke and validates the ET-1-induced MCAO model for examination of the role of the brain renin-angiotensin system in ischaemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.